Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 2
Submit an article Journal homepage
129
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Immunotherapy with Oral, Heat-Killed, Mycobacterium Vaccae in Patients with Moderate to Advanced Pulmonary Tuberculosis

Diana Dlugovitzky1 Universidad Nacional de Rosario, Santa Fe3100, (2000)Rosario, ArgentinaView further author information
,
Rodolfo Notario1 Universidad Nacional de Rosario, Santa Fe3100, (2000)Rosario, ArgentinaView further author information
,
Diego Martinel-Lamas1 Universidad Nacional de Rosario, Santa Fe3100, (2000)Rosario, ArgentinaView further author information
,
Gladys Fiorenza1 Universidad Nacional de Rosario, Santa Fe3100, (2000)Rosario, ArgentinaView further author information
,
Miguel Farroni2 Hospital I. Carrasco de Rosario, Boulevard Avellaneda1402, 2000Rosario, ArgentinaView further author information
,
Christina Bogue2 Hospital I. Carrasco de Rosario, Boulevard Avellaneda1402, 2000Rosario, ArgentinaView further author information
,
Cynthia Stanford3 Centre for Infectious Disease & International Health, Windeyer Institute of Medical Sciences, UCL, 46 Cleveland Street, LondonW1T 4JF, UK.Tel.: +44 189 273 [email protected]View further author information
&
John Stanford3 Centre for Infectious Disease & International Health, Windeyer Institute of Medical Sciences, UCL, 46 Cleveland Street, LondonW1T 4JF, UK.Tel.: +44 189 273 [email protected]View further author information
 show all
Pages 159-169 | Published online: 05 Mar 2010

Bibliography

  • Hughes ACC : Streptomycin in tuberculosis. In: Modern Practice in Tuberculosis. (Chapter 17, Volume 1). Holmes Sellars T, Livingstone JL (Eds). Butterworth and Company, London, UK, 301–314 (1952).
  • Borgdorff MW , FloydK, BroekmansJF: Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries.Bull. World Health Organ.80(3) , 217–227 (2002).
  • World Health Organization (WHO): The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance 2000. WHO/CDC/TB/ 200.278/. Geneva, Switzerland (2000).
  • World Health Organization (WHO): Report of the meeting of the WHO Global Task Force on XDR-TB. Geneva, Switzerland, 9–10 October 2006.
  • World Health Organization (WHO): The global MDR-TB and XDR-TB response plan 2007–2008. WHO/HTM/TB/2007.387(2009).
  • World Health Organization (WHO): Report of the expert consultation on immunotherapeutic interventions for tuberculosis. WHO/TDR/IRM/07.1(2007).
  • Churchyard MD , KaplanG, FallowsDet al.: Advances in immunotherapy for tuberculosis.Clin. Chest Med.30 , 769–782 (2009)
  • Bottasso OA , BayML Besedovsky H, del Rey A: Immuno-endocrine alterations during human tuberculosis as an integrated view of disease pathology. Neuroimmunomodulation16 , 68–77 (2009).
  • Rook GA : Th2 cytokines in susceptibility to tuberculosis.Curr. Mol. Med.7(3) , 327–337 (2007).
  • Stanford JL , StanfordCA, GrangeJM: Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis.Front. Biosci.9 , 1701–1719 (2004).
  • Corlan E , MaricaC, MacaveiCet al.: Immunotherapy with Mycobacterium vaccae. 1. In the treatment of newly diagnosed pulmonary tuberculosis in Romania.Respir. Med.91 , 13–19 (1997).
  • Bahr GM , ShaabanMA, GabrielM et al.: Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle71 , 259–266 (1990).
  • Onyebujoh P , AbdulmuminiT, RobinsonSet al.: Immunotherapy for tuberculosis in African conditions.Respir. Med.89 , 199–207 (1995).
  • Dlugovitzky D , BottassoO, DomininoJC et al.: Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae(SRL 172). Respir. Med.93 , 557–562 (1999).
  • Dlugovitzky D , FiorenzaG, FarroniMet al.: Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis.Respir. Med.100 , 1079–1087 (2006).
  • Dlugovitzky D , FiorenzaG, Martinel-LamasD et al.: The potential for immunotherapy with heat-killed Mycobacterium vaccae in respiratory medicine. Immunotherapy1(6) , 933–947 (2009).
  • Johnson JL , KamyaRM, OkweraAet al.: Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda–Case Western Reserve University Research Collaboration.J. Infect. Dis.181 , 1304–1312 (2000).
  • Durban Immunotherapy Trial Group: Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet354 , 116–119 (1999).
  • Stanford JL , StanfordCA, GrangeJM: Environmental echoes.Sci. Prog.84 , 105–124 (2001).
  • Farid R , EtemadiA, MehvarMet al.: Mycobacterium vaccae immunotherapy in the treatment of multi-drug-resistant tuberculosis: a preliminary report.Iranian J. Med. Sci.19 , 37–39 (1994).
  • Corlan E , MaricaC, MacaveiCet al.: Immunotherapy with Mycobacterium vaccae. 2. In the treatment of chronic or relapsed tuberculosis in Romania.Respir. Med.91 , 21–29 (1997).
  • Stanford JL , StanfordCA, GrangeJMet al.: Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis?Respir. Med.95 , 444–447 (2001).
  • Reid S , Van Niekerk AA: Injection risks and HIV transmission in the Republic of South Africa. Int. J. STD AIDS20(12) , 816–819 (2009).
  • Stainsby KJ : Development of a tuberculosis vaccine for the badger. PhD Thesis. University of London (1989).
  • Zuany-Amorim C , SawickaE, ManliusC et al.: Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med.8 , 625–629 (2002).
  • Hernandez-Pando R , PavonL, ArriagaKet al.: Pathogenesis of tuberculosis exposed to low and high doses of an environmental mycobacterial saprophyte before infection.Infect. Immun.65(8) , 3317–3327 (1997).
  • Hernandez-Pando R , AguilarD, OrozcoHet al.: Orally administered Mycobacterium vaccae modulates expression of immunoregulatory molecules in Balb-c mice with pulmonary tuberculosis.Clin. Vaccine Immunol.15(11) , 1730–1736 (2008).
  • Stanford JL , GrangeJM: The meaning and structure of species as applied to mycobacteria.Tubercle55 , 143–152 (1974).
  • Stanford J , StanfordC, StansbyGet al.: The common mycobacterial antigens and their importance in the treatment of disease.Curr. Pharm. Des.15 , 1248–1260 (2009).
  • Matzinger P : Tolerance, danger, and the extended family.Ann. Rev. Immunol.12 , 991–1045 (1994).
  • Cohen IR , YoungDB: Autoimmunity, microbial immunity and the immunological homunculus (Immunculus).Immunol. Today2 , 264–271 (1991).
  • Gebert A , RothkotterHJ, PabstR: M cells in Peyer‘s patches in the intestine.Int. Rev. Cytol.167 , 91–159 (1996).
  • Maraveyas A , BabanB, KennardD et al.: Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood leucocytes. Ann. Oncol.10 , 817–824 (1999).
  • Stanford JL , StanfordCA, O‘BrienM, GrangeJM: Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung.Eur. J. Cancer44 , 224–227 (2008).
  • Patel PM , SimS, O‘DonnellDO et al.: An evaluation of a preparation of Mycobacterium vaccae(SRL172) as an immunotherapeutic agent in renal cancer. Eur. J. Cancer44 , 216–223 (2008).
  • von Reyn CF , MarshBJ, WaddellRDet al.: Cellular immune responses to mycobacteria in healthy and human immunodeficiency virus positive subjects in the United States after a five dose schedule of Mycobacterium vaccae vaccine.Clin. Infect. Dis.27 , 1517–1520 (1998).
  • Waddell RD , ChintuC, LeinADet al.: Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccine for the prevention of HIV associated tuberculosis.Clin. Infect. Dis.30(Suppl. 3) , S309–S315 (2000).
  • Vuola JM , RistolaMA, ColeBet al.: Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial.AIDS17 , 2351–2355 (2003).
  • Mwinga A , NunnA, NgwiraB et al.: Mycobacterium vaccae(SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised, placebo-controlled trial. Lancet360 , 1050–1055 (2002).
  • Von Reyn CF , MteiL, ArbeitRDet al.: Prevention of tuberculosis in BCG-primed, HIV-infected adults boosted with an inactivated whole cell mycobacterial vaccine.AIDS (2009) (In press).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.